Australia's CSL catapulted into the number two position among flu vaccine manufacturers when it acquired Novartis' flu vaccines operations last year; it's now shooting to surpass industry leader Sanofi in 5 to 10 years. But first, unit president Gordon Naylor needs to get operations consolidated and making money, and so the newly formed Seqirus is conducting a labor force review.
Months after its formation last fall, CSL's flu vaccines unit Seqirus is a loss-making entity. However, leadership there believes the operation can achieve "industry leadership" in 5 to 10 years by relying on a move into quadrivalent vaccines, the launch of Fluad and emerging markets growth.
Seqirus--the world's second largest flu vaccine player formed CSL's purchase of Novartis flu vaccines--this week said it's expanding in the U.K. It'll spend £15.3 million ($21.3 million) on a new flu vaccine manufacturing site in Speke, an announcement the company made as it opened a £6.8 million warehouse there.
It was just 6 months ago that vaccines specialist CSL closed on its $275 million buyout of Novartis' influenza vaccines operations, getting three additional plants in the process. But the company says more capacity is needed and expansion is already underway in the U.K.
The U.S. has its first publicly available adjuvanted seasonal flu vaccine in Fluad, formerly a Novartis shot that is now owned by CSL's Seqirus unit.